DSGN · Design Therapeutics, Inc.
$11.87
-0.01 (-0.08%)
At close · Jul 28
Market Cap
$741.36M
Shares
62.46M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$11.87
Open$11.88
Day$11.46–12.14
52W$3.76–17.25
Avg vol 30d836K
Short int5.7M · 9.1% float · 6.4d
Short vol64%
Last earningsApr 28, 2026
DataMar 2021–Jul 2026
Filing10-Q · Apr 28
Up next
Next earnings call
Feb 20, 2027
Est · unconfirmed
· in 29 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Apr 28, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+13%
above
Price vs 50-day avg
−4%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
60%
mid-range
Momentum
relative strength
1-month return
−11%
trailing
6-month return
+14%
trailing
YTD return
+27%
this year
Relative strength
+7%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $12 › 200d $11 — 50d above 200d
Institutional flow
Accumulating
18 of 124 funds reported for Jun 30 · net +59.0K sh shares · +5 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
9.08% of float · ▼ -0.8% MoM · 6.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
124 holders — near 3-yr high, broad support
Squeeze score
63
elevated · 0–100
Fundamentals
EPS growth
−39%
Y/Y
Free cash flow
$-54.6M
Balance sheet
$16.9M
net cash
Quant / Vol
risk profile
Volatility
82%
annualized · 1-yr
Max drawdown
−36%
past year
ATR
7.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+13%
Bullish
Price vs 50-day avg
−4%
Neutral
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
60%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $12 › 200d $11 — 50d above 200d
Institutional flow
Accumulating
18 of 124 funds reported for Jun 30 · net +59.0K sh shares · +5 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
9.08% of float · ▼ -0.8% MoM · 6.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
124 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $4
Now $12 · 60%
52-wk high $17
vs 200-day avg +13%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DSGN
this stock
Design Therapeutics, Inc.
|
$741.36M | +26.5% | — | — | 9.1% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.3% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.57B | +8.2% | +46.2% | 28.4 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.95B | -9.8% | +20.8% | 16.3 | 3.3% |
|
ARGX
Argenx SE
|
$55.61B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DSGN | +0.0% | -11.1% | +14.0% | -18.0% | +26.6% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | +1.0% | -11.1% | +6.6% | -17.2% | +17.9% |
Key facts
CIK
1807120
CUSIP
25056L103
13F (30d)
18 filings
18 filers
Visit website
Investor relations